A study published in the prestigious New England Journal of Medicine in October 2014 tested a new treatment for Acute Lymphoblastic Leukemia (ALL) on terminally ill patients, 78% of whom survived at least 6 months.
Although textbooks call them rare, the incidence of carcinoid tumors is on the rise. In 1973, carcinoid tumors were diagnosed in only 8.5 people per million, while in 1994 this number increased more than 4 times to 38.4 per million.
Patients with kidney cancer have many options for drug therapy but often experience bad side effects. As the FDA considers another drug option, we don’t think the science is good enough to suggest patients will have a longer and better quality life on this new drug. Instead, we recommend waiting for more clinical data to give doctors and patients a clear idea of when tivozanib would be beneficial rather than cause more harm.
Is more medical care really better? What about all these new, expensive drugs and high-tech surgeries? Do they save lives or improve health?
ALCL, a type of cancer of the immune system, is developing in the breast area of women with breast implants more often than for women who don’t have breast implants. When women with implants have breast pain or abnormalities they need to see their primary care physician or OB/GYN to have it checked out.